SP
BravenNow
Exelixis director Smith sells $4.68m in stock after option exercise
| USA | economy | ✓ Verified - investing.com

Exelixis director Smith sells $4.68m in stock after option exercise

#Exelixis #Insider Trading #Julie Smith #Stock Options #NASDAQ:EXEL #Zanzalintinib #Cancer Treatment #Q4 Earnings

📌 Key Takeaways

  • Exelixis director Julie Smith sold $4.68 million in company stock after exercising options
  • Transactions occurred over two days at prices ranging from $43.33 to $44.50 per share
  • Smith exercised options at significantly lower prices between $18.19 and $21.69
  • Exelixis stock has gained 26% over the past year and appears undervalued at current levels
  • Company recently beat EPS expectations in Q4 2025 by 21.25%

📖 Full Retelling

Exelixis director Julie Smith sold $4.68 million worth of company stock on February 17 and 18, 2026, after exercising options to acquire the shares, with transactions occurring at prices ranging from $43.33 to $44.50 per share. The director executed a total of 106,539 shares of common stock over the two-day period, following the exercise of options to purchase these shares at significantly lower prices between $18.19 and $21.69, totaling approximately $2.06 million. On February 17, Smith exercised options for 42,422 shares at $18.19 and immediately sold them at $43.33, while the following day she exercised options for 44,087 shares at $19.39 and 20,030 shares at $21.69, subsequently selling all shares at $44.50 and $44.30 respectively. These transactions occurred as Exelixis shares traded at $44.16, with the stock demonstrating strong momentum having gained 26% over the past year and currently trading at a P/E ratio of 16.01, which according to InvestingPro analysis suggests the company appears undervalued at current levels. Following these sales, Smith directly owns 20,590 shares of Exelixis, including 9,812 shares of common stock that will be issued upon the vesting of restricted stock units.

🏷️ Themes

Insider Trading, Pharmaceutical Development, Stock Market Performance

📚 Related People & Topics

Insider trading

Insider trading

Trading using nonpublic information

# Insider Trading **Insider trading** is the trading of a public company's stock or other securities (such as bonds or stock options) based on **material, nonpublic information** about the company. While the practice is common, its legality is subject to complex regulations that vary significantly ...

View Profile → Wikipedia ↗

Julie Smith

Topics referred to by the same term

Julia or Julie Smith may refer to:

View Profile → Wikipedia ↗
Zanzalintinib

Zanzalintinib

Drug currently undergoing clinical studies

Zanzalintinib (also known as XL092) is an inhibitor of several receptor tyrosine kinases, including VEGFR2, MET, and the TAM kinases AXL and MERTK. It could potentially be used to treat colorectal cancer and renal cell carcinoma (RCC). It is being developed by Exelixis. STELLAR-303 is a phase 3, ran...

View Profile → Wikipedia ↗

Exelixis

American biotechnology company

Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.

View Profile → Wikipedia ↗

Entity Intersection Graph

Connections for Insider trading:

🌐 SEC filing 5 shared
👤 New York Stock Exchange 4 shared
👤 Rachel Haurwitz 3 shared
🌐 ZWS 2 shared
🌐 Biopharmaceutical 2 shared
View full profile

Deep Analysis

Why It Matters

Exelixis director Julie Smith sold $4.68m in shares after exercising options, highlighting insider activity and potential confidence in the stock's value. The transaction underscores the company's strong recent performance and may influence investor perception.

Context & Background

  • Director exercised options to acquire 106,539 shares at $18.19-$21.69 and sold them at $43.33-$44.50
  • Exelixis shares gained 26% over the past year and trade at a P/E of 16.01
  • Company reported Q4 2025 earnings beat EPS forecast but missed revenue expectations

What Happens Next

Analysts have raised price targets and maintained buy ratings, suggesting continued optimism. Future developments may include further insider sales, new drug approvals, and quarterly earnings releases.

Frequently Asked Questions

Why did Julie Smith exercise and sell the options?

She likely wanted to realize gains after the stock appreciated from option exercise price to market price.

What does this mean for shareholders?

Insider selling can signal confidence but may also raise concerns; overall market reaction depends on broader fundamentals.

Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry U.S. stocks end lower after hawkish Fed minutes; Walmart guidance falls short Gold largely flat as investors weigh geopolitical tensions, hawkish Fed minutes Berenberg sees more than 50% upside in this small-cap software stock Morgan Stanley identifies best gas stocks amid AI data center boom (South Africa Philippines Nigeria) Exelixis director Smith sells $4.68m in stock after option exercise By Investing.com Insider Trading Published 02/19/2026, 07:25 PM Exelixis director Smith sells $4.68m in stock after option exercise 0 EXEL -0.70% Director Julie Smith of EXELIXIS, INC. (NASDAQ:EXEL) sold a total of 106,539 shares of common stock on February 17 and 18, 2026, for approximately $4.68 million. The sales occurred at prices ranging from $43.33 to $44.50. The sales followed the exercise of options to acquire a total of 106,539 shares of Exelixis common stock, for a total value of $2,060,953. These options were exercised at prices between $18.19 and $21.69. On February 17, Smith exercised options to acquire 42,422 shares at $18.19 and sold the same amount at $43.33. On February 18, she exercised options to acquire 44,087 shares at $19.39 and 20,030 shares at $21.69, subsequently selling 44,087 shares at $44.50 and 20,030 shares at $44.30.The transactions occurred while Exelixis shares trade at $44.16, with the stock showing strong momentum after gaining 26% over the past year. According to InvestingPro analysis, the company appears undervalued at current levels, trading at a P/E ratio of 16.01. The platform offers 11 additional ProTips for EXEL, along with comprehensive Pro Research Reports covering 1,400+ US equities. Following these transactions, Smith directly owns 20,590 shares of Exelixis, Inc., which includes 9,812 shares of common stock that will be issued upon the vesting of restricted stock units. In other recent news, Exelixis reported its fourth-quarter 2025 earnings, showcasing an earnings per share...
Read full article at source

Source

investing.com

More from USA

News from Other Countries

🇬🇧 United Kingdom

🇺🇦 Ukraine